CARLSBAD, Calif., Oct. 26, 2015 /PRNewswire/ -- Isis
Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has
earned a $5 million milestone payment
from GSK related to the initiation of a Phase 1 study of
ISIS-GSK4-LRx (formerly ISIS-GSK4Rx) in
healthy volunteers. ISIS-GSK4-LRx is one of five
drugs in development with GSK and is designed to treat patients
with an undisclosed ocular disorder.
About ISIS and GSK
GSK and Isis have established an
alliance focused on leveraging antisense technology to develop
drugs to treat rare and infectious diseases. This alliance
provides GSK with access to Isis' expertise in RNA-targeted drug
discovery and development, with Isis retaining responsibility for
the discovery and development of drugs to the alliance targets from
inception to proof-of-concept. GSK has the option to license
each antisense program at a particular stage in development.
Current development-stage programs include ISIS-HBVRx
for patients with hepatitis B virus, ISIS-GSK4-LRx for
patients with an undisclosed ocular disorder,
ISIS-RHO-2.5Rx for patients with autosomal dominant
retinitis pigmentosa, ISIS-GSK6-LRx for patients with an
undisclosed viral disorder and ISIS-TTRRx, which is in
Phase 3 development for patients with transthyretin
amyloidosis. To date, Isis has generated nearly $135 million from GSK as its partnered programs
have advanced in development.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is the leading
company in RNA-targeted drug discovery and development focused on
developing drugs for patients who have the highest unmet medical
needs, such as those patients with severe and rare diseases.
Using its proprietary antisense technology, Isis has created a
large pipeline of first-in-class or best-in-class drugs, with over
a dozen drugs in mid- to late-stage development. Drugs
currently in Phase 3 development include volanesorsen, a drug Isis
is developing and plans to commercialize through its wholly owned
subsidiary, Akcea Therapeutics, to treat patients with familial
chylomicronemia syndrome and familial partial lipodystrophy;
ISIS-TTRRx, a drug Isis is developing with GSK to treat
patients with all forms of TTR amyloidosis; and
ISIS-SMNRx, a drug Isis is developing with Biogen to
treat infants and children with spinal muscular atrophy.
Isis' patents provide strong and extensive protection for its drugs
and technology. Additional information about Isis is
available at www.isispharm.com.
ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This
press release includes forward-looking statements regarding Isis'
alliance with GSK, the discovery, development, activity,
therapeutic and commercial potential and safety of
ISIS-GSK4-L. Any statement describing Isis' goals,
expectations, financial or other projections, intentions or beliefs
is a forward-looking statement and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. Isis' forward-looking
statements also involve assumptions that, if they never materialize
or prove correct, could cause its results to differ materially from
those expressed or implied by such forward-looking
statements. Although Isis' forward-looking statements reflect
the good faith judgment of its management, these statements are
based only on facts and factors currently known by Isis. As a
result, you are cautioned not to rely on these forward-looking
statements. These and other risks concerning Isis' programs
are described in additional detail in Isis' annual report on Form
10-K for the year ended December 31,
2014, and its most recent quarterly report on Form 10-Q,
which are on file with the SEC. Copies of these and other
documents are available from the Company.
In this press release, unless the context requires otherwise,
"Isis," "Company," "we," "our," and "us" refers to Isis
Pharmaceuticals and its subsidiaries.
Isis Pharmaceuticals® is a registered trademark of
Isis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark
of Isis Pharmaceuticals, Inc.
Logo -
http://photos.prnewswire.com/prnh/20130807/LA60006LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/isis-pharmaceuticals-earns-5-million-from-gsk-for-initiation-of-phase-1-study-of-isis-gsk4-l-rx-300165647.html
SOURCE Isis Pharmaceuticals, Inc.